長陽科技(688299.SH):公司採取以自主研發為主,合作研發為輔的研發形式
格隆匯8月2日丨長陽科技(688299.SH)近期在接待機構投資者調研時表示,公司採取以自主研發為主,合作研發為輔的研發形式,公司尖端材料研究院負責產品的研發和設計、行業情報的收集以及專利成果的申報。在自主研發方面,公司從研發項目立項、研發費用投入及研發成果評定等方面制定了一系列完善的研發管理制度,設立基膜製備、合成技術、精密塗布/複合、精密加工、光學設計等技術開發中心;在研發流程上面,建立產品開發IPD流程,從產品概念、計劃、開發、驗證、發佈、生命週期管理6個階段,建立了一個涵蓋流程概覽、階段流程、子流程和模板的分層結構框架,搭建了全面的項目管理體系。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.